Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

The combination of Typhonium flagelliforme extract and natural interferons effectively reduces tumor growth in mice.

Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Upadacitinib effectively treated severe hair loss in a child.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Retinoids can help treat skin pigmentation disorders by affecting melanin production.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

JAK inhibitors may help improve symptoms in adults with APECED.

Lack of functional CYLD in mice leads to early aging and cancer.

Tofacitinib may help treat severe hair loss, but more research is needed.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Promising cancer treatments were found, but the manufacturer closed.

Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

Hydroxytyrosol helps reduce liver injury by blocking certain inflammation pathways.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

JAK inhibitors are effective treatments for alopecia areata.